Sanggenon C inhibits proliferation of breast cancer cells and reduces HIF-1α/VEGF pathway activity under hypoxia conditions

Junyuan Qu,Jing Li,Yongqiang Ma,Zhihui Wang
DOI: https://doi.org/10.4314/tjpr.v22i8.4
2023-09-15
Tropical Journal of Pharmaceutical Research
Abstract:Purpose: To evaluate the function and mechanism of sanggenon C (SC) on breast cancer (BC) cells.Methods: The effect of SC on malignant processes of BC was studied through cell counting kit-8, colony formation, flow cytometry, Transwell, wound-healing and western blot experiments. Besides, the related mechanism of action was explored using western blot assay.Results: SC reduced the cell viability of MDA-MB-231 and MCF-7 cells with half-maximal concentration of (IC50) value of 17.09 and 17.32 μM, respectively. SC also decreased the area ratio of colonies in the plate, but increased the apoptosis and G0/G1 phase arrest in both cell lines. Furthermore, SC decreased the number of invasion cells, but elevated the relative wound width of both cells. Moreover, SC treatment neutralized the hypoxia-induced level of HIF-1α/VEGF signaling.Conclusion: SC suppresses proliferation, mobility and invasion, but induces apoptosis and G0/G1 phase arrest in BC cells, as well as deceased HIF-1α/VEGF pathway activity under hypoxia conditions. The findings of this study reveal that SC is a potential agent for BC management.
pharmacology & pharmacy
What problem does this paper attempt to address?